MARKET

BIAFW

BIAFW

bioAffinity Tech
NASDAQ
0.4500
-0.0025
-0.55%
Closed 09:37 04/01 EDT
OPEN
0.4500
PREV CLOSE
0.4525
HIGH
0.4500
LOW
0.4500
VOLUME
1.50K
TURNOVER
--
52 WEEK HIGH
0.8121
52 WEEK LOW
0.0525
MARKET CAP
--
P/E (TTM)
-0.0519
1D
5D
1M
3M
1Y
5Y
1D
bioAffinity CyPath Lung unit sales jump 146% in Q1 2026
Reuters · 17h ago
Weekly Report: what happened at BIAFW last week (0323-0327)?
Weekly Report · 2d ago
bioAffinity Technologies to host live virtual physician roundtable; CyPath Lung adoption grows in pulmonary practice discussion
Reuters · 03/25 12:02
Weekly Report: what happened at BIAFW last week (0316-0320)?
Weekly Report · 03/23 10:08
bioAffinity Technologies releases CyPath Lung case study highlighting 92% sensitivity in nodules under 20 mm
Reuters · 03/17 11:45
New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures
Barchart · 03/17 06:45
Weekly Report: what happened at BIAFW last week (0309-0313)?
Weekly Report · 03/16 10:08
bioAffinity Technologies FY2025 net loss widens 66% to USD 14.91 million on revenue down 34% to USD 6.16 million
Reuters · 03/13 12:02
More
About BIAFW
bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatment. Its segments include Diagnostic Research and Development (R&D) and Laboratory Services. Its Diagnostic R&D segment includes research and development and clinical development on diagnostic tests. Its Laboratory services include all the operations of Village Oaks and PPLS, in addition to sales and marketing of CyPath Lung from bioAffinity. Its first product, CyPath Lung, addresses the need for noninvasive detection of early-stage lung cancer. The CyPath Lung test enables physicians to more confidently identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening.

Webull offers bioAffinity Technologies Inc stock information, including NASDAQ: BIAFW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIAFW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIAFW stock methods without spending real money on the virtual paper trading platform.